Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018.

After the successful divestment of Emapalumab related activities, we now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

Products, services, technology

Access to κλ body bispecific and multispecific antibody platform.

Internal Bispecific programs available for partnership (please refer to current pipeline

https://www.lightchainbio.com/our-focus/pipeline.html

Cooperation possibilities

We aim to work with partners to develop truly human bispecific antibodies in different therapeutic areas. Several collaborative models are possible, depending on the partner’s objectives. We can provide access to the technology, generate the bispecifc leads for our partner and further progress them

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    1999
  • Number of employees in Switzerland
    50-149
Key business